Form 4: Veracyte EVP Annie McGuire Sells Shares Under 10b5-1 Plan

Veracyte's General Counsel Annie McGuire sold 3,176 shares and had 3,292 shares withheld for taxes, totaling over $310,000 in transactions.

Summary

• Annie McGuire, EVP and General Counsel of Veracyte, Inc., executed several stock transactions in early June 2026.
• On June 2, 2026, 3,292 shares were withheld to cover tax obligations from vesting restricted stock units at a price of $47.80.
• On June 4, 2026, a total of 3,176 shares were sold in two tranches at weighted average prices of $49.31 and $50.12.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan established on August 29, 2025.
• Following these transactions, McGuire retains ownership of 137,240 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and the executive retains a significant majority of their holdings.

Positives

• The reporting person maintains a significant stake of 137,240 shares in the company.
• Sales were made under a Rule 10b5-1 plan, which helps mitigate concerns about insider trading based on non-public information.
• The stock price for the sales ($49.31 $50.12) shows a slight premium over the tax withholding price ($47.80).

Negatives

• A total of 6,468 shares left the executive's direct holding through withholding and sales.
• Executive selling can sometimes be perceived by the market as a lack of confidence, regardless of the planned nature of the trades.

Risks

• Potential market perception of executive divestment impacting short-term sentiment.
• Stock price volatility as indicated by the range of sale prices from $48.84 to $50.40 within a single day.

Future Outlook

No specific guidance provided; transactions were part of a pre-set plan and do not necessarily reflect management's view on future performance.

Management Comments

• The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

Industry Context

StockSavvy.ai notes that routine insider sales under 10b5-1 plans are common in the biotech and diagnostics sector to manage executive compensation and liquidity without triggering insider trading concerns.

Comparison to Industry Standards

• Veracyte's executive retention of over 137,000 shares is consistent with high-level management stakes in mid-cap diagnostic companies like Exact Sciences or Guardant Health.
• The use of 10b5-1 plans is a standard best practice for corporate governance in the U.S. to provide transparency to shareholders.

Corporate Governance

Stakeholder Impact

• Shareholders may see this as routine liquidity management by an executive.
• No direct impact on customers, employees, or creditors.

Next Steps

• Monitoring of further insider transactions under the existing 10b5-1 plan.

Key Dates

Recommendation

The filing represents routine insider activity with no change to company fundamentals or strategic direction. The executive remains heavily invested in the company's success.

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Annie McGuire, Stock Sale, 10b5-1 Plan, Diagnostics